RadNet (NASDAQ:RDNT) Announces Quarterly Earnings Results

Posted by Geri Gentry on Aug 10th, 2026

RadNet (NASDAQ:RDNT – Get Free Report) issued its quarterly earnings results on Monday. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.09, FiscalAI reports. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The business had revenue of $622.72 million for the quarter, compared to the consensus estimate of $610.87 million.

RadNet Stock Performance

Shares of NASDAQ RDNT opened at $72.39 on Monday. The company has a 50 day simple moving average of $60.95 and a two-hundred day simple moving average of $61.66. The stock has a market cap of $5.69 billion, a price-to-earnings ratio of -402.14 and a beta of 1.36. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.79. RadNet has a 12 month low of $50.82 and a 12 month high of $85.84.

Insiders Place Their Bets

In related news, CEO Cornelis Wesdorp sold 4,750 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total transaction of $276,022.50. Following the completion of the transaction, the chief executive officer directly owned 69,075 shares in the company, valued at $4,013,948.25. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David L. Swartz sold 2,699 shares of the company’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $53.89, for a total transaction of $145,449.11. Following the completion of the sale, the director directly owned 177,013 shares in the company, valued at approximately $9,539,230.57. The trade was a 1.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.14% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On RadNet

A number of institutional investors have recently modified their holdings of the stock. Captrust Financial Advisors grew its position in RadNet by 10.3% during the fourth quarter. Captrust Financial Advisors now owns 3,343 shares of the medical research company’s stock valued at $238,000 after buying an additional 312 shares during the period. State of Wyoming raised its position in shares of RadNet by 267.1% in the fourth quarter. State of Wyoming now owns 3,194 shares of the medical research company’s stock worth $228,000 after acquiring an additional 2,324 shares during the period. Glenmede Investment Management LP purchased a new stake in shares of RadNet during the 3rd quarter worth about $262,000. First Trust Advisors LP purchased a new stake in shares of RadNet during the 3rd quarter worth about $219,000. Finally, Headlands Technologies LLC grew its position in shares of RadNet by 292.3% during the 2nd quarter. Headlands Technologies LLC now owns 2,244 shares of the medical research company’s stock valued at $128,000 after acquiring an additional 1,672 shares during the period. Hedge funds and other institutional investors own 77.90% of the company’s stock.

Wall Street Analyst Weigh In

RDNT has been the topic of several research analyst reports. Barclays dropped their target price on RadNet from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. Weiss Ratings downgraded RadNet from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, May 12th. Zacks Research lowered RadNet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Finally, Jefferies Financial Group restated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, RadNet has an average rating of “Moderate Buy” and a consensus price target of $87.43.

Read Our Latest Report on RadNet

RadNet Company Profile

(Get Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.